daunorubicin has been researched along with tamoxifen in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.52) | 18.7374 |
| 1990's | 6 (28.57) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 6 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hansch, C; Khwaja, TA; Selassie, CD | 1 |
| Hargrove, P; Kim, RB; Lan, LB; Lecureur, V; Schuetz, EG; Schuetz, JD; Sun, D | 1 |
| Balakrishnan, L; Janvilisri, T; Reuter, G; Shahi, S; van Veen, HW; Venter, H | 1 |
| Casciano, CN; Clement, RP; Johnson, WW; Wang, EJ | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ghosh, I; Manoharlal, R; Prakash, O; Prasad, R; Puri, N; Sharma, M | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Glover, DJ | 1 |
| Adams, M; Andreeff, M; Berman, E; Clarkson, B; Duigou-Osterndorf, R; Godfrey, L | 1 |
| Kessel, D | 1 |
| Bennett, JM; Cassileth, PA | 1 |
| Berman, E; Lin, S; McBride, M; Menedez-Botet, C; Tong, W | 1 |
| Berman, E; McBride, M; Tong, W | 1 |
| Ayesh, S; Shao, YM; Stein, WD | 1 |
| Casciano, CN; Clement, RP; Johnson, WW; Wang, E | 1 |
| Chen, B; Cheng, J; Dong, Y; Gao, F; Sheng, M; Wang, T; Zhang, P; Zhou, Y | 1 |
| Chen, BA; Cheng, J; Dong, Y; Gao, F; Qian, XJ; Sheng, M; Wang, T; Zhou, Y | 1 |
| Du, J; Guo, J; Ju, RJ; Li, RJ; Lu, WL; Men, Y; Tian, W; Wang, XX; Yao, HJ; Ying, X; Zhang, Y; Zhou, J | 1 |
| Chang, ND; Hao, ZF; Li, BX; Li, MH; Peng, HS; Ren, YC; Shao, M; Shen, ZY; Sun, SL; Yang, BF; Yu, H | 1 |
| Ju, RJ; Li, XT; Li, XY; Liu, L; Lou, JN; Lu, WL; Shi, JF; Sun, MG; Zeng, F; Zhang, CX | 1 |
1 review(s) available for daunorubicin and tamoxifen
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for daunorubicin and tamoxifen
| Article | Year |
|---|---|
Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Drug Administration Schedule; Drug Resistance, Multiple; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tamoxifen | 1995 |
19 other study(ies) available for daunorubicin and tamoxifen
| Article | Year |
|---|---|
Structure-activity relationships of antineoplastic agents in multidrug resistance.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Survival; Cricetinae; Dactinomycin; Drug Resistance; Leukemia L1210; Mice; Regression Analysis; Structure-Activity Relationship; Tumor Cells, Cultured | 1990 |
Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein.
Topics: Amino Acid Sequence; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Cells, Cultured; Cloning, Molecular; DNA, Complementary; Humans; Karyotyping; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Sequence Homology, Amino Acid | 2000 |
Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis.
Topics: Antineoplastic Agents, Hormonal; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cholesterol; Estradiol; Gene Expression; Humans; Lactococcus lactis; Neoplasm Proteins; Progesterone; Sterols; Tamoxifen; Testosterone; Tritium | 2003 |
Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Binding Sites; Biological Transport, Active; Biomarkers; Cells, Cultured; Drug Interactions; Fluorescent Dyes; Humans | 2003 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
Topics: Candida albicans; Membrane Transport Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Substrate Specificity | 2010 |
New approaches to the chemotherapy of melanoma.
Topics: Alkaloids; Amifostine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazine; Daunorubicin; Humans; Lomustine; Melanoma; Nitrosourea Compounds; Paclitaxel; Procarbazine; Tamoxifen; Taurine; Thiotepa; Vincristine; Vindesine | 1991 |
Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype.
Topics: Cell Division; Daunorubicin; Drug Resistance; Flow Cytometry; Humans; Kinetics; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Phenotype; Tamoxifen; Tumor Cells, Cultured; Verapamil; Vinblastine | 1991 |
Interactions among membrane transport systems: anthracyclines, calcium antagonists and anti-estrogens.
Topics: Animals; Antibiotics, Antineoplastic; Biological Transport; Calcium Channel Blockers; Daunorubicin; Doxorubicin; Drug Resistance; Estrogen Antagonists; Kinetics; Leukemia P388; Mice; Naphthacenes; Nifedipine; Nitrendipine; Tamoxifen; Verapamil | 1986 |
Effectiveness of acute nonlymphocytic leukemia induction chemotherapy in acute lymphocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubicin; Humans; Leukemia, Lymphoid; Middle Aged; Mitolactol; Prednisone; Tamoxifen; Thioguanine; Time Factors; Vincristine | 1985 |
Comparative activity of tamoxifen and N-desmethyltamoxifen in human multidrug resistant leukemia cell lines.
Topics: Daunorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Humans; Leukemia, Myeloid; Phenotype; Tamoxifen; Tumor Cells, Cultured | 1994 |
Mutually co-operative interactions between modulators of P-glycoprotein.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Daunorubicin; Drug Resistance, Multiple; Drug Synergism; Kinetics; Leukemia P388; Mefloquine; Tamoxifen; Tumor Cells, Cultured; Verapamil; Vinblastine | 1997 |
The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein.
Topics: 3T3 Cells; Adenosine Triphosphate; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Cell Line; CHO Cells; Cricetinae; Daunorubicin; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Genes, MDR; Humans; Hydrolysis; Mice; Paclitaxel; Piperidines; Pyridines; Rhodamine 123; Tamoxifen; Vinblastine | 2001 |
[Effect of tetrandrine and droloxifene on the reversion of drug resistance of K562/A02 cell line and induction of apoptosis].
Topics: Alkaloids; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzylisoquinolines; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; K562 Cells; Tamoxifen; Tumor Cells, Cultured | 2002 |
[Study on the relationship between [Ca2+]i and the MDR formation in K562/A02 cells].
Topics: Alkaloids; Benzylisoquinolines; Calcium; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; K562 Cells; Tamoxifen | 2004 |
Effects of stealth liposomal daunorubicin plus tamoxifen on the breast cancer and cancer stem cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Daunorubicin; Drug Delivery Systems; Drug Synergism; Female; Humans; In Situ Nick-End Labeling; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Particle Size; Tamoxifen; Tissue Distribution; Xenograft Model Antitumor Assays | 2010 |
The liposomal daunorubicin plus tamoxifen: improving the stability, uptake, and biodistribution of carriers.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Daunorubicin; Dose-Response Relationship, Drug; Drug Carriers; Drug Screening Assays, Antitumor; Drug Stability; Female; Flow Cytometry; Humans; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Confocal; Structure-Activity Relationship; Tamoxifen; Tissue Distribution | 2012 |
Multifunctional targeting daunorubicin plus quinacrine liposomes, modified by wheat germ agglutinin and tamoxifen, for treating brain glioma and glioma stem cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Daunorubicin; Glioma; Liposomes; Mice; Neoplastic Stem Cells; Quinacrine; Tamoxifen; Wheat Germ Agglutinins | 2014 |